1579514-47-8

Basic information

• Product Name: (S)-methyl 2-(4-bromophenyl)-3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate
• Synonyms: (S)-methyl 2-(4-bromophenyl)-3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate
• CAS NO: 1579514-47-8
• Molecular Weight: 549.465
• Mol File: 1579514-47-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-methyl 2-(4-bromophenyl)-3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-methyl 2-(4-bromophenyl)-3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate(1579514-47-8)
• EPA Substance Registry System: (S)-methyl 2-(4-bromophenyl)-3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate(1579514-47-8)

Safety Data

• Hazardous Substances Data: 1579514-47-8(Hazardous Substances Data)

Upstream product

• 586-76-5 4-Bromobenzoic acid 
• 1579514-43-4 2-(4-bromophenyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one hydrochloride 
• 1579514-41-2 tert-butyl 2-(4-bromophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate 
• 1579514-39-8 4-tert-butyl 4-(4-bromobenzamido)-4-carbamoylpiperidine-1-carboxylate 
• 288154-18-7 tert-butyl 4-amino-4-carbamoylpiperidine-1-carboxylate 
• 1067230-65-2 (R)-tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate 
• 1579514-45-6 methyl 2-(4-bromophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate 

Downstream Products

• 1579514-49-0 (R)-methyl 2-(4-bromophenyl)-4-oxo-3-(pyrrolidin-3-ylmethyl)-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate hydrochloride 

Relevant articles and documents

IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.